[Federal Register Volume 63, Number 210 (Friday, October 30, 1998)]
[Notices]
[Page 58409]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-29073]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Human Immunodeficiency
Virus (HIV) ENV-Coded Peptide Capable of Eliciting HIV-Inhibiting
Antibodies in Mammals
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH),
Department of Health and Human Services, in contemplating the grant of
a limited field of use exclusive world-wide license to practice the
invention embodied in U.S. Patent No. 5,562,905, issued October 8, 1996
(U.S. Patent Application Serial No. 07/324,027, filed March 20, 1989),
entitled ``Human Immunodeficiency Virus (HIV) ENV-Coded Peptide Capable
of Eliciting HIV-Inhibiting Antibodies in Mammals'' and non-U.S. patent
applications claiming priority to U.S. patent application SN 07/148,692
entitled ``Synthetic Antigen Evoking Anti-HIV Response'' to BioQuest,
Inc. of Houston, Texas, U.S.A. These patent rights are either assigned
or exclusively licensed to the United States of America.
DATES: Only written comments and/or application for a license which are
received by the NIH Office of Technology Transfer on or before January
28, 1999 will be considered.
ADDRESSES: Requests for a copy of this issued patent or applications,
inquiries, comments, and other materials relating to the contemplated
license should be directed to: Carol A. Salata, Technology Licensing
Specialist, Office of Technology Transfer, National Institutes of
Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804;
Telephone: (301) 496-7735 ext 232; Facsimile: (301) 402-0220; E-Mail:
[email protected]
SUPPLEMENTARY INFORMATION: The patent describes the use of a chemically
synthesized 15 amino acid peptide, designated peptide 1-69, which has
the sequence of amino acids numbers 308 to 322 of the human
immunodeficiency virus-1 (HIV-1) IIIB env-coded protein to immunize
animals against HIV. Peptide 1-69 elicited antibodies in animals that
block HIV proliferation and block HIV-induced cell fusion in cell
culture.
It is anticipated that this license may be limited to the field of
treatment or prevention of HIV using a specific 15 amino acid peptide
(RIQRGPGRAFVTIGK).
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
This prospective exclusive license may be granted unless within 90 days
from the date of this published notice, NIH receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
Applications for a license filed in response to this notice will be
treated as objections to the grant of the contemplated license.
Comments and objections submitted in response to this notice will not
be made available for public inspection, and, to the extent permitted
by law will not be released under the Freedom of Information Act, 5
U.S.C. 552.
Dated: October 21, 1998.
Jack Spiegel,
Director, Division of Technology, Development and Transfer, Office of
Technology Transfer.
[FR Doc. 98-29073 Filed 10-29-98; 8:45 am]
BILLING CODE 4140-01-M
